Sign In
Buy YMAB
$8.61
+0 (+0%)
At Close: Dec 15, 2025
Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China
09:00am, Monday, 13'th Sep 2021
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”), NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and c
Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma
09:00am, Friday, 10'th Sep 2021
NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercial
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q2 2021 Results - Earnings Call Transcript
11:22am, Sunday, 08'th Aug 2021
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q2 2021 Results - Earnings Call Transcript
YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
07:46pm, Thursday, 05'th Aug 2021
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 22.06% and 43.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock
Recap: Y-mAbs Therapeutics Q2 Earnings
06:02pm, Thursday, 05'th Aug 2021
Shares of Y-mAbs Therapeutics (NASDAQ:YMAB) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 47.52% year over year to ($0.53), which bea
Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021
04:05pm, Thursday, 29'th Jul 2021
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended
Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China
08:37am, Tuesday, 06'th Jul 2021
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of nov
NEW YORK, June 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com
Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma
09:05am, Friday, 04'th Jun 2021
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and com
Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America
04:01pm, Wednesday, 19'th May 2021
NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and comm
Y-mAbs Announces Update on SADA Technology
09:00am, Thursday, 13'th May 2021
NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and comm
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q1 2021 Results - Earnings Call Transcript
04:33pm, Sunday, 09'th May 2021
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q1 2021 Results - Earnings Call Transcript
Y-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue Cancer
12:18pm, Tuesday, 20'th Apr 2021
Y-mAbs Therapeutics Inc (NASDAQ: YMAB) recently concluded a Type B meeting with the FDA regarding omburtamab in CNS/leptomeningeal metastasis from neuroblastoma. The company received requests from
Y-mAbs Therapeutics' (YMAB) CEO Claus Moller on Q4 2020 Results - Earnings Call Transcript
03:18pm, Friday, 26'th Feb 2021
Y-mAbs Therapeutics' (YMAB) CEO Claus Moller on Q4 2020 Results - Earnings Call Transcript
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and c
